SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing ...
Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results